Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(acetolyloxy)-n-(5-nitro-2-thiazolyl)benzamide
2. Alinia
3. Colufase
4. Cryptaz
5. Daxon
6. Heliton
7. Ntz
8. Taenitaz
1. 55981-09-4
2. Alinia
3. 2-((5-nitrothiazol-2-yl)carbamoyl)phenyl Acetate
4. Nitazoxamide
5. Daxon
6. Nitazoxanidum [inn-latin]
7. Nitazoxanida [inn-spanish]
8. 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl Acetate
9. Benzamide, 2-(acetyloxy)-n-(5-nitro-2-thiazolyl)-
10. [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] Acetate
11. 2-(acetolyloxy)-n-(5-nitro-2-thiazolyl)benzamide
12. Nsc 697855
13. Nsc697855
14. Ntz
15. 2-acetyloxy-n-[(5-nitro-2-thiazolyl)]benzamide
16. Nsc-697855
17. Nsc-760057
18. N-(5-nitrothiazol-2-yl)salicylamide Acetate Ester
19. Ph 5776
20. Ph-5776
21. Nitazoxanide (alinia, Annita)
22. Soa12p041n
23. Nitazoxanida
24. Cryptaz
25. [2-[(5-nitrothiazol-2-yl)carbamoyl]phenyl] Acetate
26. Ncgc00090774-01
27. Nitazoxanid
28. Nitazoxanidum
29. Colufase
30. Heliton
31. Dsstox_cid_13757
32. Dsstox_rid_79095
33. Dsstox_gsid_33757
34. Phavic-1
35. Smr000466367
36. Alinia (tn)
37. Azt + Nitazoxanide
38. Cas-55981-09-4
39. Einecs 259-931-8
40. Nitazoxanide (usan/inn)
41. (2-((5-nitro-2-thiazolyl)carbamoyl)phenyl)acetat
42. Brn 1225475
43. Unii-soa12p041n
44. N-(5-nitro-2-thiazolyl)salicylamide Acetate (ester)
45. Nitrazoxanide
46. Pacovanton
47. Dexidex
48. Kidonax
49. Nitazox
50. Paramix
51. Nitax
52. Toza
53. Nitazoxanide [usan:inn:ban]
54. Alinia(tm)
55. Mfcd00416599
56. O-(n-(5-nitrothiazol-2-yl)carbamoyl)phenyl Acetate
57. Nitazoxanide- Bio-x
58. Salicylamide, N-(5-nitro-2-thiazolyl)-, Acetate (ester)
59. Cpd000466367
60. Nitazoxanide [mi]
61. Nitazoxanide [inn]
62. Ncimech_000843
63. Nitazoxanide [usan]
64. Chembl1401
65. Nitazoxanide [vandf]
66. 2-(acetyloxy)-n-(5-nitro-2-thiazolyl)benzamide
67. Oprea1_263587
68. Schembl40981
69. Nitazoxanide [mart.]
70. Mls000759492
71. Mls001424074
72. Mls006010127
73. Nitazoxanide [usp-rs]
74. Nitazoxanide [who-dd]
75. Dtxsid5033757
76. Chebi:94807
77. Nitazoxanide [green Book]
78. Nitazoxanide, >=98% (hplc)
79. Ntz;nsc 697855
80. Hms2051l04
81. Hms3393l04
82. Hms3655m11
83. Hms3715f10
84. Nitazoxanide [orange Book]
85. Pharmakon1600-01503843
86. Bcp13918
87. Hy-b0217
88. Zinc3956788
89. Tox21_111018
90. Tox21_201226
91. Bdbm50075050
92. Ccg-35851
93. Mmv688991
94. Nsc760057
95. Stk395664
96. Akos015915393
97. Tox21_111018_1
98. Ac-1302
99. Db00507
100. Ks-1160
101. Nc00246
102. Ncgc00090774-02
103. Ncgc00090774-03
104. Ncgc00090774-04
105. Ncgc00090774-05
106. Ncgc00258778-01
107. Bn164151
108. Nci60_034935
109. Ft-0601547
110. N1031
111. Nitrazoxanide 100 Microg/ml In Acetonitrile
112. S1627
113. Sw197626-2
114. 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl Acetate
115. D02486
116. Ab00639988-07
117. Ab00639988-09
118. Ab00639988_10
119. Ab00639988_11
120. 2-(acetyloxy)-n-(5-nitro-2-thiazolyl)-benzamide
121. 981n094
122. A830877
123. Sr-01000759418
124. Q-201475
125. Q2943789
126. Sr-01000759418-9
127. Salicylamide, N-(5-nitro-2-thiazolyl)- Acetate (ester)
128. Z1514087129
129. Nitazoxanide, United States Pharmacopeia (usp) Reference Standard
130. Acetic Acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] Ester
131. Zox
| Molecular Weight | 307.28 g/mol |
|---|---|
| Molecular Formula | C12H9N3O5S |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 307.02629157 g/mol |
| Monoisotopic Mass | 307.02629157 g/mol |
| Topological Polar Surface Area | 142 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 428 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Alinia |
| PubMed Health | Nitazoxanide (By mouth) |
| Drug Classes | Antiprotozoal |
| Drug Label | Alinia Tablets and Alinia for Oral Suspension contain the active ingredient, nitazoxanide, a synthetic antiprotozoal agent for oral administration. Nitazoxanide is a light yellow crystalline powder. It is poorly soluble in ethanol and practically ins... |
| Active Ingredient | Nitazoxanide |
| Dosage Form | Tablet; For suspension |
| Route | oral; Oral |
| Strength | 100mg/5ml; 500mg |
| Market Status | Prescription |
| Company | Romark |
| 2 of 2 | |
|---|---|
| Drug Name | Alinia |
| PubMed Health | Nitazoxanide (By mouth) |
| Drug Classes | Antiprotozoal |
| Drug Label | Alinia Tablets and Alinia for Oral Suspension contain the active ingredient, nitazoxanide, a synthetic antiprotozoal agent for oral administration. Nitazoxanide is a light yellow crystalline powder. It is poorly soluble in ethanol and practically ins... |
| Active Ingredient | Nitazoxanide |
| Dosage Form | Tablet; For suspension |
| Route | oral; Oral |
| Strength | 100mg/5ml; 500mg |
| Market Status | Prescription |
| Company | Romark |
For the treatment of diarrhea in adults and children caused by the protozoa Giardia lamblia, and for the treatment of diarrhea in children caused by the protozoan, Cryptosporidium parvum. Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency.
FDA Label
The general effect of this medication is the prevention of microbe activity through disruption of important energy pathways for survival and proliferation. Nitazoxanide exhibits antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, an essential reaction need for anaerobic energy metabolism of various microorganisms. Sporozoites of Cryptosporidium parvum and trophozoites of Giardia lamblia are therefore inhibited, relieving symptoms of diahrrea. Interference with the PFOR enzyme-dependent electron transfer reaction may only be one of the many pathways by which nitazoxanide exhibits antiprotozoal activity.
Antiparasitic Agents
Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)
P - Antiparasitic products, insecticides and repellents
P01 - Antiprotozoals
P01A - Agents against amoebiasis and other protozoal diseases
P01AX - Other agents against amoebiasis and other protozoal diseases
P01AX11 - Nitazoxanide
Absorption
The relative bioavailability of the suspension compared to the tablet was 70%. When administered with food the AUC and Cmax increased by two-fold and 50%, respectively, for the tablet and 45 to 50% and ≤ 10%, respectively, for the oral suspension.
Route of Elimination
Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately 2/3 of the oral dose of nitazoxanide is excreted in the faeces and 1/3 in the urine.
Clearance
Nitazoxanide is cleared in the urine and feces. The metabolite, tizoxanide, is also found in the urine, plasma, and breastmilk. The drug is not found unchanged in the urine.
The active metabolite of this drug is tizoxanide (desacetyl-nitazoxanide). The initial reaction in the metabolic pathway of Nitazoxanide is hydrolysis to tizoxanide, followed by conjugation, primarily by glucuronidation to tizoxanide glucuronide. The oral suspension bioavailability of this drug is not equivalent to that of the oral tablets. Compared to the to the tablet, the bioavailability of the suspension was 70%. When administered with food, the AUCt of tizoxanide and tizoxanide glucuronide in plasma is increased to almost two-fold and the maximum concentration is increased by almost 50% compared to when ingested without food. When the oral suspension was ingested with food, the AUC of tizoxanide and tizoxanide glucuronide increased by approximately 50% and the Cmax increased by less than 10%.
7.3h
The most widely accepted mechanism of NTZ is believed to be the disruption of the energy metabolism in anaerobic microbes by inhibition of the pyruvate: ferredoxin/flavodoxin oxidoreductase (PFOR) cycle. In parasitic-protozoa, Nitazoxanide also induces lesions in the cell membranes and depolarizes the mitochondrial membrane while inhibiting quinone oxidoreductase NQO1, nitroreductase-1 and protein disulphide isomerase enzymes. In addition, this drug also inhibits the glutathione-S-transferase (a major detoxifying enzyme) and modulates the Avr-14 gene, encoding for the alpha-type subunit of glutamate-gated chloride ion channel present in nematodes. Aside from its well understood non-competitive inhibition of the PFOR in anaerobic bacteria, NTZ also demonstrates various other antibacterial mechanisms. It inhibits pyruvate dehydrogenase in E Coli, disrupts the membrane potential and pH homeostasis in the Mycobacterium tuberculosis, suppresses the chaperone/usher (CU) pathway of the gram-negative bacteria, and stimulates host macrophage autophagy in tuberculosis patients. NTZ also suppresses viral replication by inhibiting the maturation of the viral hemagglutinin and the viral transcription factor immediate early 2 (IE2) as well as by activating the eukaryotic translation initiation factor 2 (an antiviral intracellular protein). Lastly, NTZ exhibits an inhibitory effect on tumor cell progression by altering drug detoxification (glutathione-S-transferase P1), unfolded protein response, autophagy, anti-cytokines activity, and c-Myc inhibition.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.
About the Company : With more than 30 years of experience, Gentec Pharmaceutical Group has established itself as one of the leaders in raw materials and ingredients for the food, dietary and nutrition...
Jai Radhe Sales is your partner for all your sourcing needs.
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
About the Company : Capital Farma offers a comprehensive range of pharmaceutical solutions. Our API offering includes active ingredients sourced exclusively from top European manufacturers, ensuring t...
About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...
About the Company : Kreative Organics Private Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs) for the world market. Kreative started operations in 1990. Kreative was established ...
About the Company : Nira Life Sciences Pvt Ltd was initially established in 2012 at GIDC Bamanbore, Taluka- Chotila, District- Surendranagar, Gujarat, India. We stand out as a rapidly expanding pharma...
About the Company : Rakshit is an integrated API manufacturing company. Established in 2000. Today Rakshit has emerged a dependable and strong manufacturer of key APIs & intermediates for global marke...
About the Company : Rumit group of companies is a young, dynamic & Robustly growing company established in 1993. We specialise in pharmaceutical raw material, Bulk API, dye stuff, dyes intermediates &...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
GENFIT is launching a clinical program with nitazoxanide (NTZ) in this disease. A Phase 1 study to evaluate pharmacokinetics and pharmacodynamics in patients with varying degrees of hepatic impairment is expected to start in 4Q21 with clinical data expected end of 2022.
Lead Product(s): Nitazoxanide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Lead Product(s) : Nitazoxanide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GENFIT Provides Pipeline Update and Launch of New Clinical Programs
Details : GENFIT is launching a clinical program with nitazoxanide (NTZ) in this disease. A Phase 1 study to evaluate pharmacokinetics and pharmacodynamics in patients with varying degrees of hepatic impairment is expected to start in 4Q21 with clinical data expec...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
May 11, 2021
Details:
NT-300 is an oral, broad-spectrum antiviral drug designed to provide antiviral concentrations of drug to the respiratory tract throughout twice-daily dosing.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Brand Name: NT-300
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Romark’s Investigational Covid-19 Drug Lowers Disease Progression in Trial
Details : NT-300 is an oral, broad-spectrum antiviral drug designed to provide antiviral concentrations of drug to the respiratory tract throughout twice-daily dosing.
Product Name : NT-300
Product Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2021
Details:
Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.
Lead Product(s): Nitazoxanide
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Lead Product(s) : Nitazoxanide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Launches Authorized Generic Version of Alinia®
Details : Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2021
Details:
The Phase 3 clinical trial aims to evaluate safety and efficacy of Romark's investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Brand Name: NT-300
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Romark Initiates New Phase 3 Clinical Trial Of NT-300 For The Treatment Of COVID-19
Details : The Phase 3 clinical trial aims to evaluate safety and efficacy of Romark's investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
Product Name : NT-300
Product Type : Small molecule
Upfront Cash : Not Applicable
August 11, 2020
Details:
Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients. Novalead is enrolling 100 patients across six centres for the trial which is expected to start in a month’s time.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2020
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novalead to Start Trial on Anti- Parasitic Drug for Covid-19
Details : Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients. Novalead is enrolling 100 patients across six centres for the trial which is expected to start in a month’s time.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
May 25, 2020
Details:
Clinical development program for NT-300 includes trials addressing prevention and treatment of COVID-19 and other viral respiratory illnesses.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Romark Initiates Phase 3 Clinical Trials Of NT-300 For COVID-19
Details : Clinical development program for NT-300 includes trials addressing prevention and treatment of COVID-19 and other viral respiratory illnesses.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Ecuador
Brand Name : Abanix
Dosage Form : Tablet
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ecuador
Regulatory Info :
Registration Country : Ecuador
Brand Name : Abanix
Dosage Form : Tablet
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ecuador
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Granules
Dosage Strength : 600MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Egypt
Brand Name : Antidiazox
Dosage Form : Powder for Suspension
Dosage Strength : 100MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Egypt
Regulatory Info : Generic
Registration Country : India
Brand Name : Netazox-DT
Dosage Form : DISPERSIBLE TABLET
Dosage Strength : 200MG
Packaging : 10x1x6 Blisters
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info :
Registration Country : Egypt
Brand Name : Crptosept
Dosage Form : Tablet
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Egypt
Regulatory Info : RX
Registration Country : USA
Brand Name : NITAZOXANIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Packaging :
Approval Date : 2020-11-27
Application Number : 213820
Regulatory Info : RX
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : ALINIA
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Packaging :
Approval Date : 2004-07-21
Application Number : 21497
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : ALINIA
Dosage Form : TABLET; ORAL
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number : 21818
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : DC Granules and Tablets
Dosage Strength : 71.43MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 500MG
USFDA APPLICATION NUMBER - 21497
DOSAGE - FOR SUSPENSION;ORAL - 100MG/5ML
USFDA APPLICATION NUMBER - 21498
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Controlled & Modified Release
Thickeners and Stabilizers
Disintegrants & Superdisintegrants
Direct Compression
Lubricants & Glidants
Taste Masking
Granulation
Film Formers & Plasticizers
Co-Processed Excipients
Solubilizers
Rheology Modifiers
Chewable & Orodispersible Aids
Empty Capsules
API Stability Enhancers
Vegetarian Capsules
Coloring Agents
Emulsifying Agents
Topical
Parenteral
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
Company :
Nitazoxanide
Drug Cost (USD) : 5,382,165
Year : 2022
Prescribers : 2618
Prescriptions : 3366
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 1,791,011
Year : 2021
Prescribers : 473
Prescriptions : 642
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 5,063,807
Year : 2021
Prescribers : 2167
Prescriptions : 2770
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 120,348
Year : 2020
Prescribers : 47
Prescriptions : 47
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 11,406,351
Year : 2020
Prescribers : 2902
Prescriptions : 3988
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 13,663,259
Year : 2019
Prescribers : 4181
Prescriptions : 5608
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 11,892,396
Year : 2018
Prescribers : 4126
Prescriptions : 5535
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 10,051,858
Year : 2017
Prescribers : 4348
Prescriptions : 5748
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 7,042,245
Year : 2016
Prescribers : 4600
Prescriptions : 5973
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nitazoxanide
Drug Cost (USD) : 4,138,683
Year : 2015
Prescribers : 4739
Prescriptions : 6131
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
FDF DOSSIERS
Reply
27 Aug 2024
Reply
29 Jun 2021
Reply
03 Jul 2020
Reply
08 May 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
72
PharmaCompass offers a list of Nitazoxanide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nitazoxanide manufacturer or Nitazoxanide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nitazoxanide manufacturer or Nitazoxanide supplier.
PharmaCompass also assists you with knowing the Nitazoxanide API Price utilized in the formulation of products. Nitazoxanide API Price is not always fixed or binding as the Nitazoxanide Price is obtained through a variety of data sources. The Nitazoxanide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nitazoxanide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nitazoxanide, including repackagers and relabelers. The FDA regulates Nitazoxanide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nitazoxanide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nitazoxanide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nitazoxanide supplier is an individual or a company that provides Nitazoxanide active pharmaceutical ingredient (API) or Nitazoxanide finished formulations upon request. The Nitazoxanide suppliers may include Nitazoxanide API manufacturers, exporters, distributors and traders.
click here to find a list of Nitazoxanide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nitazoxanide DMF (Drug Master File) is a document detailing the whole manufacturing process of Nitazoxanide active pharmaceutical ingredient (API) in detail. Different forms of Nitazoxanide DMFs exist exist since differing nations have different regulations, such as Nitazoxanide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nitazoxanide DMF submitted to regulatory agencies in the US is known as a USDMF. Nitazoxanide USDMF includes data on Nitazoxanide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nitazoxanide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nitazoxanide suppliers with USDMF on PharmaCompass.
A Nitazoxanide written confirmation (Nitazoxanide WC) is an official document issued by a regulatory agency to a Nitazoxanide manufacturer, verifying that the manufacturing facility of a Nitazoxanide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nitazoxanide APIs or Nitazoxanide finished pharmaceutical products to another nation, regulatory agencies frequently require a Nitazoxanide WC (written confirmation) as part of the regulatory process.
click here to find a list of Nitazoxanide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nitazoxanide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nitazoxanide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nitazoxanide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nitazoxanide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nitazoxanide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nitazoxanide suppliers with NDC on PharmaCompass.
Nitazoxanide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nitazoxanide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nitazoxanide GMP manufacturer or Nitazoxanide GMP API supplier for your needs.
A Nitazoxanide CoA (Certificate of Analysis) is a formal document that attests to Nitazoxanide's compliance with Nitazoxanide specifications and serves as a tool for batch-level quality control.
Nitazoxanide CoA mostly includes findings from lab analyses of a specific batch. For each Nitazoxanide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nitazoxanide may be tested according to a variety of international standards, such as European Pharmacopoeia (Nitazoxanide EP), Nitazoxanide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nitazoxanide USP).
Comment (14)
